A B S T R A C T The human fetal liver is capable of synthesizing the biologically active form of the second (C2) and fourth (C4) components of complement as early as 8 wk after conception, and the inhibitor of Cl (Cl INH) as early as 11 wk after conception. Biologically active C3 was produced in vitro by fetal liver obtained at 14 wk gestation. These conclusions were based on the observations that isolated fetal livers produced biologically active C2, C3, C4, and C1 INH, that this production was temperature dependent and reversibly inhibited by well-known inhibitors of protein synthesis, and that 'C-labeled amino acids were incorporated into proteins immunochemically identical with these proteins. The data suggested that a large mononuclear cell was the cell type in the fetal liver that synthesized C2 and C4.
INTRODUCTION
It is known that the developing fetus can synthesize immunoglobulins and is capable of mounting an effective cellular and humoral immune response to specific antigens (1, 2) . With a few notable exceptions, however, the ontogeny of the complement system, particularly in man, has not been investigated. The few studies of the ontogeny of human complement that are available have suggested that human fetal tissues are capable of synthesizing the first (Cl), third (C3), and fourth (C4) components of complement, and that this capacity appears early in embryogenesis. For example, we have shown that segments of large and small intestine, obtained from a human fetus at 19 wk gestation, were capable of producing functionally active Cl in vitro Received for publication 20 August 1971 and in revised form 27 October 1971. (3) . It has also been shown' that human fetal tissues are capable of synthesizing proteins immunochemically identical with C3 (2, 4) and C4 (4), although no direct evidence was obtained that these components are produced by the fetus in a functionally active form. Recent developments in complement research have made it possible to detect in vitro the biosynthesis of biologically active complement components. As a consequence, the tissues and, in some cases, the cell types that synthesize most of the complement components have been identified (5) . In earlier studies, we showed that fragments of lung, spleen, and lymph node, and bone marrow and peritoneal exudate cells obtained from adult guinea pigs are capable of synthesizing the hemolytically active form of the second component of complement (C2) in short-term tissue culture (6) . Furthermore, it was demonstrated that macrophages isolated from these tissues synthesize C4, as well as C2 (7) . The methods developed in the course of these studies were applied to an investigation of the ontogeny of individual complement components in the human fetus.
In this report, evidence will be presented that the liver is the major site of synthesis of C2, C3, and C4 and the natural inhibitor of Cl (Cl INH)1 in the human fetus. This conclusion was based on the observations that liver obtained from human fetuses at gestational ages ranging from 8 to 22 wk produced C2, C3, C4, and C1 INH in vitro, that this production was highly temperature dependent, was reversibly inhibited by puromycin, cycloheximide, and actinomycin D, and that 1C-labeled amino acids were incorporated into proteins immunochemically identical with C2, C3, C4, and C1 INH. Smaller amounts of C2 and C4 pro-1 Abbreviations used in this paper: C1 INH, C1 inhibitor, VBS, veronal-buffered saline.
duction were detected in short-term cultures of spleen and thymus, but not in muscle, lung, kidney, or amniotic cell cultures.
METHODS
The source and preparation of reagents for the hemolytic assay of biologically active complement components have been described in detail (8) . Methods for the hemolytic titration of human C4 and C2 and the preparation of rat CEDTA (rat serum diluted 1/5 in EDTA buffer, final molarity of EDTA 0.01) are described in reference 9. Quantitative determinations of Cl INH activity were performed as given in reference 10. Hemolytic assays of C3 activity were performed in the following way: 0.2 ml of a suspension of EAC14 (7.5 X 107 ml) was mixed with 0.2 ml of the sample and 0.4 ml of a mixture containing functionally purified human C2, C5, C6, and C7. After the mixtures were incubated at 30°C for 30 min, 0.4 ml of a solution containing human C8 and C9 was added. The resulting mixtures were then incubated at 37'C for 1 hr, then centrifuged, and the optical density of the supernatant fluid read at a wavelength of 412 nm. Veronal-buffered saline-dextrose (, = 0.075) buffer was used throughout. Controls in which the sample was omitted yielded less than 2% lysis. human serum and placed in wells cut in 1% agarose opposite specific rabbit antibodies to human C2, C3, C4, C1 INH, and transferrin.' After a 48 hr incubation, the immunodiffusion plates were washed for 48 hr in 0.15 M NaCl and then an additional 48 hr in distilled water. The plates were then dried and exposed to Kodak X-ray film for 4-6 wk.
Actinomycin D, puromycin, and cycloheximide were purchased from Nutritional Biochemicals Corporation (Cleveland, Ohio), and each was used at a concentration of [1] [2] ,ug/ml in M199 FCS in experiments to test the effect of known inhibitors of protein synthesis on complement production. RESULTS C2 and C4 biosynthesis. Preliminary studies indicated that the amount of C2 and C4 production by fetal liver was at least 20-40 times the production of C2 and C4 by equal weights of spleen and thymus. Furthermore, there was no detectable production of C2 or C4 by muscle, kidney, lung, or amniotic cells. Accordingly, fetal liver was used in all of the following experiments.
Effect of temperature on C2 and C4 synthesis. Fragments of fetal liver were incubated at 37°C (95% air, 5% C02) or at 4°C in 3.5 ml of M199 FCS. At timed intervals, 0.1 ml portions of the media were removed, diluted immediately in VBS-sucrose, and the C4 and C2 content estimated. As shown in Fig. 1 the tissues, were about the same as the rates of production by tissues maintained at 370C throughout. The data given in Table I show that the in vitro production of C2 by the liver was independent of the gestational age of the fetus. At 370C in M199 FCS, C2 was produced at a rate of about 8.9 X 108 effective molecules, and in the older fetuses, C4 was produced at a rate of about 7.2 X 108 effective molecules per 100 mg liver per hr. Liver obtained from fetuses at 11 wk gestation or less, produced C4 at a rate of about 2.5 X 108 effective molecules per 100 mg per tissue per hr.
Effect of inhibitors of protein synthesis on C2 and C4 production. The following experiments were designed to determine the effect of puromycin and actinomycin D, two well-known inhibitors of protein synthesis, on the production of hemolytically active C2 and C4 by isolated fragments of human fetal liver. Measured portions of minced liver (35-50 mg each) removed from 10 Fg/ml had no effect on the stability or measurement of preformed C2 and C4. Fig. 4 , show that incubation of fetal liver in (4) anti-transferrin. were then removed and the medium mixed with the 14C-labeled amino acids (1 GCi/ml). These control mixtures were then handled exactly as the experimental preparations, and no radiolabel was detected in the specific precipitin lines.
DISCUSSION
The ontogeny of several serum proteins has been studied by demonstrating that the fetal tissues are capable of synthesizing these proteins in vitro (2) . Modem methods for the study of in vitro biosynthesis of complement have made it possible to utilize a similar approach for an investigation of the ontogeny of serum complement components. The data presented in this report provide direct evidence that in the human fetus the liver is a major site of synthesis of biologically active C2 and C4. Furthermore, the capacity to synthesize these proteins was present in liver obtained as early as 8 wk after conception.
It is interesting to note that the rate of C2 production by fetal liver was independent of the gestational age of the fetus. In contrast, C4 production by fetal livers obtained at 8, 10, and 11 wk gestation was less than one-third the average rate of production by livers that were obtained from older fetuses. At (2, 4) . In the present report, evidence was presented that isolated fragments of human fetal liver are capable of producing functionally active C3 in vitro. These observations support the conclusion that the fetal liver is a site of C3 biosynthesis, and are in accord with other studies that suggested that the adult human liver is the major, if not only, site of C3 synthesis (16) .
Human fetal liver in culture was, in addition, capable of incorporating "4C-labeled amino acids into molecules immunochemically identical with C2, C3, C4, and Cl INH. Incorporation of the radiolabel was temperature dependent and was inhibited by cycloheximide.
The studies presented in this report provide a basis for detailed investigations of the biosynthesis of individual complement components in the genetic complement deficiency states. It is apparent that with such studies it may be possible to localize the specific biochemical abnormalities responsible for these defects and, in some cases, may offer a rational basis for therapeutic trials.
